Source Feed: Global News - Canada
Author: Globalnews Digital
Publication Date: July 16, 2026 - 09:35
Stay informed
Unpublished Opinions
Add Alzheimer’s drug lecanemab to Canada’s public drug plans, agency says
July 16, 2026
Lecanemab is an antibody that targets the buildup of amyloid plaque in the brain, which is believed to be an underlying cause of the disease.
August 6, 2026 - 06:55 | | The Globe and Mail
August 6, 2026 - 06:52 | | The Globe and Mail
August 6, 2026 - 06:46 | | The Globe and Mail



Comments
Be the first to comment